Company news

Acurx Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 15, 2023

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

March 5, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

November 13, 2022

Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022

October 25, 2022

Acurx Announces Scientific Oral and Poster Presentations at IDWeek

October 16, 2022

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update

August 14, 2022

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

August 1, 2022

Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering

July 24, 2022

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update

May 10, 2022

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

March 16, 2022

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

February 6, 2022

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

December 5, 2021

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

November 11, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

November 7, 2021

Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek

October 3, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference

September 26, 2021

Acurx Pharmaceuticals to Join the Russell Microcap Index®

September 1, 2021

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

August 15, 2021

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

August 11, 2021

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome

July 6, 2021

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

June 30, 2021

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

June 28, 2021

Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock

June 24, 2021

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.